Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

NCT: NCT05904028 · RECRUITING

NCT IDNCT05904028
StatusRECRUITING
Start Date2023-11-09
Completion2027-07-30

Brief Summary

Home optical coherence tomography- guided treatment versus treat and extend for the management of neovascular age-related macular degeneration.

Frequently Asked Questions

What is Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD?

Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD is a clinical trial registered under NCT05904028. Current status: RECRUITING.

What is the status of NCT05904028?

The current status of NCT05904028 (Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD) is: RECRUITING.

When did Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD start?

Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD started on 2023-11-09.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑